This is an author produced version of a paper published in:

*Postgraduate Medical Journal*

Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa27204

---

**Paper:**

*Postgraduate Medical Journal*, postgradmedj-2015-133740

http://dx.doi.org/10.1136/postgradmedj-2015-133740

---

This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions. When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO database to judge whether or not it is copyright safe to add this version of the paper to this repository.

http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/
The clinical management of hyponatraemia

David M Williams¹*, Maire Gallagher¹, Joel Handley¹, Jeffrey W Stephens¹,²

¹Department of Diabetes & Endocrinology, Morriston Hospital, ABMU Health Board, Swansea, United Kingdom
²Welsh Institute of Metabolic and Obesity Surgery, Medicine, Swansea, United Kingdom

*David M Williams, Academic Foundation Year 1 Doctor, Department of Diabetes & Endocrinology, Morriston Hospital, Swansea, SA6 6NL.
Maire Gallagher, Foundation Year 2 Doctor, Department of Diabetes & Endocrinology, Morriston Hospital, Swansea, SA6 6NL
Joel Handley, Academic Foundation Year 1 Doctor, Department of Diabetes & Endocrinology, Morriston Hospital, Swansea, SA6 6NL
Jeffrey W Stephens, Clinical Professor of Diabetes & Honorary Consultant Physician, Department of Diabetes & Endocrinology, Morriston Hospital, Swansea, SA6 6NL

*To whom correspondence should be addressed
Telephone: +44 1792 704078
Fax: +44 1792 703214
Email: david.williams@doctors.org.uk
Abstract

Hyponatraemia is the most common electrolyte disorder seen in clinical practice and the consequences can range from minor symptoms to life-threatening complications including seizures and cardiorespiratory distress. These effects occur as a result of fluid shifts due to deranged serum tonicity and subsequent cerebral oedema. The appropriate assessment and management of patients with hyponatraemia is not always achieved in clinical practice, which is partly related to challenges in teaching with limited clinical guidance. Recently, the European Society of Endocrinology, European Society of Intensive Care Medicine and European Renal Association–European Dialysis and Transplant Association produced clinical practice guidelines to focus on appropriate investigation and management of these patients.

Within this manuscript, we highlight the key points from these guidelines which are most pertinent to doctors of all specialities to improve the care of patients with this common electrolyte disorder.
Background

Hyponatraemia is the commonest electrolyte disorder seen in hospital inpatients in the UK. Approximately 15% of inpatients have a serum sodium concentration <135mmol/L, 4% <130mmol/L and 2% <125mmol/L [1]. This prevalence is greater in the acute critical setting such as intensive care, where approximately 30% of patients have a serum sodium <134mmol/L [2]. Clinical presentation and subsequent management is dependent on the nature and severity of the clinical symptoms and signs, and the aetiology of the hyponatraemia. Patients with acute, severe symptoms will require specialist input for rapid correction of the serum sodium. Such patients are also at a higher risk of morbidity, length of hospital stay and mortality [1, 3]. Patients with hyponatraemia are seven times more likely to die than those without hyponatraemia in hospital [4]. Hospital doctors regularly manage patients with hyponatraemia across a range of inpatient wards, and therefore the management of this common electrolyte disorder is important in routine clinical practice. However optimal management of these patients is not always achieved, which is in part due to a lack of knowledge. Within this manuscript, we summarise the key points from the joint guidelines from the European Society of Endocrinology, European Society of Intensive Care Medicine and European Renal Association–European Dialysis and Transplant Association [5].

Hyponatraemia is defined as serum sodium <135mmol/L. It may be classified temporally (acute <48 hours; chronic >48 hours) or by the absolute serum sodium level [5]. Mild (130-135mmol/L), moderate (125-130mmol/L) or severe (<125mmol/L) hyponatraemia presents with non-specific signs and symptoms, and are summarised in Table 1. However, patients should be assessed and treated on the basis of their symptoms rather than the absolute serum sodium level or time frame in which hyponatraemia develops.
Clinical features

The clinical presentation of hyponatraemia is often non-specific but may include life-threatening seizures and cardiorespiratory arrest. Patients with mild to moderate hyponatraemia may have symptoms such as nausea, confusion and headache, whereas those with moderate to severe hyponatraemia will present with vomiting, cardiorespiratory distress, seizures and reduced consciousness [3, 5], as summarised in Table 1. A patient is likely to present with more severe symptoms if they have acute-onset hyponatraemia as cerebral oedema develops secondary to the reduced serum osmolality. In chronic hyponatraemia there is lower risk of neurological dysfunction as the brain initiates counter-regulatory mechanisms to reduce cerebral oedema, typically over a 24-48 hour period [3]. This explains the rationale for classifying acute hyponatraemia as that which occurs within 48 hours and the relative severity of the symptoms that patients’ develop [5]. Importantly, there must be a normal serum sodium concentration demonstrated in the previous 48 hours for acute hyponatraemia to be diagnosed, otherwise the assumption must be that the patient has a chronic hyponatraemia.

Table 1

<table>
<thead>
<tr>
<th>Subtle symptoms</th>
<th>Mild symptoms</th>
<th>Severe symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Gait abnormalities</td>
<td>• Nausea</td>
<td>• Vomiting</td>
</tr>
<tr>
<td>• Falls</td>
<td>• Confusion</td>
<td>• Cardiorespiratory</td>
</tr>
<tr>
<td>• Reduced concentration</td>
<td>• Headache</td>
<td>distress</td>
</tr>
<tr>
<td>• Cognitive deficits</td>
<td></td>
<td>• Abnormal and deep sleep</td>
</tr>
<tr>
<td>• Increased osteoporosis and fractures.</td>
<td></td>
<td>• Seizures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Coma</td>
</tr>
</tbody>
</table>

Table 1: Summary of clinical features associated with hyponatraemia.
The aetiology and assessment of hyponatraemia

A detailed clinical assessment of patients with mild to moderate hyponatraemia is essential, as aetiology will guide clinical management. Patients with severe or life-threatening hyponatraemia may require rapid correction of their serum sodium (see below), and therefore specialist input may be required prior to obtaining a clinical assessment.

Hyponatraemia in the presence of high serum osmolality may occur as a consequence of hyperglycaemia, termed hypertonic hyponatraemia. Hyperglycaemia may result in a fluid shift by osmosis from the intracellular to the extracellular fluid compartment, thus diluting serum sodium levels [6]. When hyperglycaemia is corrected, the sodium concentration will correct as fluid returns by osmosis to the intracellular compartment. Therefore, when treating patients with hyperglycaemia it is important to control the rate at which plasma glucose is lowered, to minimise the associated risk of cerebral oedema that can occur [7].

Once non-hypotonic hyponatraemia has been excluded, it is important to measure the serum osmolality and both the urine osmolality and sodium concentration. In the instance the serum osmolality is >275mOsmol/Kg then isotonic or hypertonic hyponatraemia is present. Conversely, if the serum osmolality is <275mOsmol/Kg, the patient has a hypotonic hyponatraemia. The urine osmolality and urinary sodium can help identify the aetiology. In most instances when the urine osmolality <100mOsmol/Kg, it is likely that the patient has excess water intake. Commonly, when the urine osmolality >100mOsmol/Kg and urinary sodium is <30mmol/L there is a low effective arterial volume (see below). In those patients with a urine osmolality >100mOsmol/kg and a urinary sodium >30mmol/L assessment of the patients extracellular fluid (ECF) status should be undertaken (see section below). If the ECF volume is low, the patient’s hyponatraemia may be secondary to diuretic use, primary adrenal
insufficiency, vomiting and cerebral or renal salt wasting. For patients who are clinically euvolemic, consider the syndrome of inappropriate diuresis (SIAD), secondary adrenal insufficiency, hypothyroidism as well as drug-induced aetiologies. This is shown in Figure 1.

**Assessing extracellular fluid status**

The assessment of ECF status is often difficult, and is most useful in patients with hyponatraemia when urine osmolality and urinary sodium levels can also be reviewed. The aetiological basis of hyponatraemia can be classified by the fluid status of the patient as hypovolemic, euvolemic or hypervolemic hyponatraemia. Major causes of hypovolemic hyponatraemia include diuretics, renal failure, and adrenal insufficiency; causes of euvolemic hyponatraemia include SIAD and hypothyroidism; hypervolemic hyponatraemia is caused by chronic medical conditions such as cardiac failure, hepatic disease, and renal disease [8]. Table 2 summarises the causes of hyponatraemia by fluid status.

<table>
<thead>
<tr>
<th>Hypovolaemia</th>
<th>Euvolaemia</th>
<th>Hypervolaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>• GI loss (vomiting, diarrhoea)</td>
<td>• SIAD</td>
<td>• Renal failure</td>
</tr>
<tr>
<td>• Diuretics (thiazides)</td>
<td>• Secondary adrenal insufficiency</td>
<td>• Heart failure</td>
</tr>
<tr>
<td>• Primary adrenal insufficiency</td>
<td>• Hypothyroidism</td>
<td>• Liver failure</td>
</tr>
<tr>
<td>• Cerebral salt wasting</td>
<td>• High water/low solute intake (primary polydipsia)</td>
<td>• Nephrotic syndrome</td>
</tr>
<tr>
<td>• Renal disease (salt-losing nephropathies)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ‘Third spacing’ (pancreatitis, sepsis, bowel obstruction)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2:** Classification of hyponatraemia based on Extracellular Fluid volume (ECF).
The clinical history will guide the assessment as the patient may have had diarrhoea, vomiting, polyuria or a pre-existing medical condition such as cardiac or renal failure. At this point in the assessment, ask about symptoms of hyponatraemia as this may change the approach to management (Figure 2). Signs of hypovolemia include dry mucous membranes, tachycardia and hypotension. Hypervolemic patients present with raised jugular venous pressure, peripheral and pulmonary oedema [9]. Euvolemia is determined primarily through the absence of other signs. However, clinical examination alone to assess a patient’s fluid status is often difficult, especially when assessing elderly patients who may demonstrate inconsistent signs [10]. Therefore, consideration of body weight, fluid balance charts and intravenous fluid prescription is also essential.

In many cases of hyponatraemia there is an increased secretion of antidiuretic hormone (ADH) which can further reduce the serum sodium level, termed SIAD. In those with hypovolemic hyponatraemia, ADH is released from the posterior pituitary gland via a baroceptor-mediated reflex, which increases renal water reabsorption. This will help to restore intravascular volume, but at the cost of reducing serum sodium levels and the serum osmolality further. In hypervolemic patients with hyponatraemia there is often a concurrent diagnosis of cardiac failure or hepatic impairment, resulting in reduced cardiac output and peripheral vasodilation respectively. This causes a similar reflex as described above and further water reabsorption resulting in both fluid overload and a chronic hyponatraemia [11].

In practice, it is difficult to know the prevalence of the different causes of hyponatraemia because often a full clinical assessment has not been completed and the causes differ between specialities and patient subgroups. Commoner causes include medication-induced hyponatraemia [8] and SIAD. A recent study in a sample of elderly patients admitted with fragility fractures, observed that hyponatraemia in >75% was potentially related to the use of
thiazide diuretics [12]. Other medications which may result in hyponatraemia include antipsychotics, antiepileptic medications, selective serotonin reuptake inhibitors (SSRIs), angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), and proton-pump inhibitors (PPIs). SIAD is described in further detail below.

Therefore patients with hyponatraemia should have serum urea and electrolytes, glucose, osmolality, and thyroid function tests measured in addition to urine analysis for osmolality and sodium concentrations. In patients with suspected adrenal insufficiency, one should also consider testing a 9am serum cortisol level or performing a short synacthen test.

**Syndrome of inappropriate diuresis**

This syndrome results from the excessive, unregulated secretion of ADH which results in the kidney’s inability to effectively dilute urine. Reduced serum osmolality and hyponatraemia result from the excess water reabsorption in the renal tubules. SIAD is the commonest cause of euvolemic hyponatraemia [13], but should be considered as a diagnosis of exclusion after other causes of hyponatraemia have been excluded [5]. Beware that the other conditions discussed previously may result in the appropriate increased secretion of ADH and may therefore present with a similar clinical picture [14].

The diagnosis of SIAD requires the exclusion of the other causes of hyponatraemia which result in the physiological secretion of ADH. The biochemical markers suggestive of increased ADH secretion include a serum osmolality <275mOsmol/kg with urine osmolality >100mOsmol/kg. The urine osmolality is inappropriately concentrated relative to the plasma osmolality, and the urinary sodium concentration is typically >30mmol/L. The patient should
be clinically euvolemic and have normal adrenal, thyroid and pituitary function. These patients should also have normal renal function and no recent history of diuretic use [13, 15]. There are many causes of SIAD, which are also summarised in Table 3. These include malignancies of the lung, gastrointestinal (GI) and genitourinary (GU) tracts; pneumonia; neurological disorders such meningitis/encephalitis, subdural haematomas and stroke. Medications such as antidepressants, antipsychotics and antiepileptic medications are also known to cause SIAD [16]. However, in practice there is often no attributable cause.

Table 3

<table>
<thead>
<tr>
<th>Malignant Disorders</th>
<th>Pulmonary Disorders</th>
<th>CNS Disorders</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma</td>
<td>Infections</td>
<td>Infection</td>
<td>Antidepressants</td>
</tr>
<tr>
<td>• Lung</td>
<td>• Bacterial or Viral Pneumonia</td>
<td>• Meningitis</td>
<td>• SSRIs and SNRIs</td>
</tr>
<tr>
<td>• Oropharynx</td>
<td>• TB</td>
<td>• Encephalitis</td>
<td>Anticonvulsants</td>
</tr>
<tr>
<td>• GI Tract</td>
<td>• Asthma</td>
<td></td>
<td>• Carbamazepine</td>
</tr>
<tr>
<td>• GU Tract</td>
<td>• Cystic Fibrosis</td>
<td>Vascular</td>
<td>• Sodium Valproate</td>
</tr>
<tr>
<td>• Lymphoma</td>
<td></td>
<td>• Subdural</td>
<td>• Lamotrigine</td>
</tr>
<tr>
<td>• Sarcoma</td>
<td></td>
<td>• Subarachnoid haemorrhage</td>
<td>Antipsychotics</td>
</tr>
</tbody>
</table>

Table 3: Summary of the aetiology of SIAD

Cerebral/Renal salt wasting syndrome

Cerebral/renal salt wasting syndrome is a rare condition which leads to a mild-to-moderate hyponatraemia, and is commonly associated with intracranial bleeds (subarachnoid haemorrhage, subdural haematomas), cerebral injury or brain tumours. The term cerebral salt
wasting syndrome is commonly used due to its significant association with the cerebral pathologies listed. However, the syndrome often occurs without cerebral pathology, and as such the term renal salt-wasting syndrome is often considered to be more appropriate [17]. The mechanism of the syndrome is thought to be initiated by the release of a natriuretic factor which results in the increased renal excretion of sodium and subsequent volume depletion. As a result of the subsequent intravascular volume depletion, there is release of ADH and increased renin-angiotensin-aldosterone activity to reduce the rate of diuresis [18]. Crucially, it must be recognised that the release of ADH in this setting is an appropriate response to the volume depletion, and this often makes it clinically difficult to differentiate cerebral/renal salt wasting syndrome from SIAD.

Investigation of these patients will demonstrate similar laboratory findings as observed in patients with SIAD, with low serum osmolality (<275mOsmol/kg), high urine osmolality (>100mOsmol/kg) and high urinary sodium concentration (>30mmol/L). However, on examination patients with cerebral salt wasting are dehydrated, and as described above, patients with SIAD are euvoletic. Treatment of cerebral salt wasting syndrome is usually best achieved with intravenous supplementation of 0.9% sodium chloride, and specialist use of fludrocortisone [19]. In most patients there is spontaneous resolution within 2 weeks, though in elderly patients prolonged treatment may be required.

**Approaches to management**

The clinical management of patients with acute hyponatraemia take account of the patient’s symptoms, the duration of onset (i.e. acute or chronic), fluid balance and absolute sodium level. The available guidelines consider the management of patients with severe and moderately severe symptoms separately as summarised in Figure 2 [5].
Management of patients with severe symptoms

The management of patients with hyponatraemia with severe symptoms is best achieved by senior and specialist doctors working in a closely monitored environment in which there is easily available blood monitoring, and as such doctors who are uncertain of appropriate management strategies should seek help from appropriate medical or critical care teams as early as possible. Treatment is initiated with an intravenous infusion of 150mls 3% hypertonic sodium chloride over 20 minutes. Following the infusion the serum sodium is measured and a further 150ml infusion can be administered whilst waiting for the result. If the patient’s symptoms have not adequately improved, continue with the intravenous hypertonic saline infusions, regularly checking the serum sodium at least every 4 hours. The hypertonic saline infusions should be stopped when the patient’s symptoms improve, the serum sodium concentration increases by 10mmol/L or the serum sodium is 130mmol/L. In patients who respond to treatment, consider a slow infusion of 0.9% sodium chloride and cause-specific treatment. In these patients, the serum sodium should be checked after 6 hours, and subsequently at 12 hours, and daily thereafter. If the patient requires concurrent fluid resuscitation, this overrides the risk of rapid correction of hyponatraemia (section below).

Management of patient’s without severe symptoms

The clinical management of hyponatraemia without severe symptoms is guided by the rate of onset. If the onset is acute, consider stopping any contributing fluids and medications. If the drop in serum sodium is >10mmol/L consider giving 150mls 3% sodium chloride over 20 minutes intravenously and measure the serum sodium after 4 hours. Following this, undertake the investigations as described above and initiate cause-specific treatment. It should be noted that this approach in management should be undertaken only with specialist supervision and facilities to regularly check serum sodium levels.
In patients with chronic hyponatraemia without severe symptoms management should consist of stopping any contributing non-essential medications or fluids. Further treatment takes account of the fluid status. Patients with hypervolemia or SIAD are best managed with fluid restriction. If there is no improvement, low-dose loop diuretics and oral sodium chloride should be started. In these patients always consider the causes of SIAD and treat appropriately. Patients with hypovolemia should be given intravenous 0.9% sodium chloride or a balanced crystalloid solution at a rate of 0.5-1.0ml/kg/hour. Importantly, asymptomatic patients with mild hyponatraemia do not warrant aggressive treatment. Guidelines frequently reference the patient’s symptoms as the most important factor when considering treatment of hyponatraemia and treatment of mild hyponatraemia is only warranted when symptomatic.

**Rapid correction of serum sodium**

The treatments outlined above may result in a rapid correction of the serum sodium and serum osmolality. In rare cases, this may precipitate osmotic demyelination syndrome (ODS), which presents in patients with changes in mental status, rapid quadriplegia, and dysphagia [20]. There is an increased risk of developing ODS in patients with SIAD, significant burns and those who chronically abuse alcohol [21]. Whilst patients with a rapidly corrected chronic hyponatraemia are considerably more likely to develop ODS [22], there is a small number of patients described in the literature who have developed ODS following rapid correction of an acute hyponatraemia [23]. As such, we should bear in mind the risks of rapidly correcting serum sodium levels in all patients with hyponatraemia.

To minimise the risk, guidelines recommend stopping the treatment of hyponatraemia if there is an increase in serum sodium >10mmol/L in the first 24 hours or >8mmol/L in each subsequent 24 hours. Close monitoring of the patient’s serum electrolytes is therefore
required, and as such aggressive management should only be sought in an appropriately close-monitored environment. In these circumstances, it is essential to seek expert advice on whether to begin an infusion of electrolyte free solutions (e.g. glucose solutions) whilst under strict fluid balance and urine output monitoring.

**Conclusion**

Hyponatraemia is a disorder which often presents non-specifically and has a considerable aetiological basis. Appropriate management of hyponatraemia takes account of the patient’s symptoms and the acute or chronic nature of onset. Appropriately educating doctors is important in improving clinical management which is often suboptimal in practice and essential in minimising the associated morbidity and mortality of the condition. The new guidelines summarised here will hopefully reduce the previous difficulty in teaching this important clinical topic to both medical students and doctors, which will ultimately improve the treatment of this common electrolyte disorder.

**Declaration of Interests**

The authors report no declarations of interest.

**Funding Statement**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Contributorship Statement

Dr David M Williams planned and wrote the manuscript, edited the manuscript and gives approval of the version to be published.

Dr Maire Gallagher created the figures and tables used in the article, critically edited the manuscript and gives approval of the version to be published.

Dr Joel Handley planned and critically edited the manuscript and gives approval of the version to be published.

Professor Jeffrey Stephens supervised the writing of the article and critically edited the completed manuscript, and gives approval of the version to be published.

Main Messages

• Hyponatraemia is a complex metabolic disorder which carries significant morbidity and mortality in hospital inpatients.

• Hyponatraemia patients require thorough examination investigation to ascertain the cause which guides further management appropriately.

• Management is not only guided by the absolute serum sodium level or underlying disorder, but guided mostly by the patient’s symptomatology.
References


